![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF714 |
Gene summary for ZNF714 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF714 | Gene ID | 148206 |
Gene name | zinc finger protein 714 | |
Gene Alias | ZNF714 | |
Cytomap | 19p12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A087WU35 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
148206 | ZNF714 | HCC1 | Human | Liver | HCC | 4.03e-13 | 1.27e+00 | 0.5336 |
148206 | ZNF714 | HCC2 | Human | Liver | HCC | 5.80e-23 | 2.89e+00 | 0.5341 |
148206 | ZNF714 | HCC5 | Human | Liver | HCC | 1.20e-19 | 1.45e+00 | 0.4932 |
148206 | ZNF714 | S014 | Human | Liver | HCC | 4.60e-02 | 1.77e-01 | 0.2254 |
148206 | ZNF714 | S015 | Human | Liver | HCC | 9.16e-07 | 2.93e-01 | 0.2375 |
148206 | ZNF714 | S016 | Human | Liver | HCC | 3.23e-06 | 1.79e-01 | 0.2243 |
148206 | ZNF714 | male-WTA | Human | Thyroid | PTC | 6.03e-26 | 2.35e-01 | 0.1037 |
148206 | ZNF714 | PTC01 | Human | Thyroid | PTC | 1.57e-21 | 4.90e-01 | 0.1899 |
148206 | ZNF714 | PTC03 | Human | Thyroid | PTC | 1.88e-02 | 3.66e-01 | 0.1784 |
148206 | ZNF714 | PTC04 | Human | Thyroid | PTC | 2.65e-14 | 4.43e-01 | 0.1927 |
148206 | ZNF714 | PTC05 | Human | Thyroid | PTC | 4.00e-21 | 1.01e+00 | 0.2065 |
148206 | ZNF714 | PTC06 | Human | Thyroid | PTC | 1.34e-30 | 9.68e-01 | 0.2057 |
148206 | ZNF714 | PTC07 | Human | Thyroid | PTC | 6.80e-34 | 8.18e-01 | 0.2044 |
148206 | ZNF714 | ATC12 | Human | Thyroid | ATC | 1.04e-14 | 4.83e-02 | 0.34 |
148206 | ZNF714 | ATC13 | Human | Thyroid | ATC | 9.59e-16 | 8.97e-02 | 0.34 |
148206 | ZNF714 | ATC4 | Human | Thyroid | ATC | 6.24e-10 | 1.14e-01 | 0.34 |
148206 | ZNF714 | ATC5 | Human | Thyroid | ATC | 1.55e-13 | 1.30e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF714 | insertion | Frame_Shift_Ins | novel | c.1614_1615insA | p.Pro539ThrfsTer40 | p.P539Tfs*40 | protein_coding | TCGA-BG-A0MU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD | |||
ZNF714 | SNV | Missense_Mutation | novel | c.247T>G | p.Leu83Val | p.L83V | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-BW-A5NQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZNF714 | SNV | Missense_Mutation | rs371085101 | c.154T>C | p.Ser52Pro | p.S52P | protein_coding | deleterious(0.02) | benign(0.331) | TCGA-DD-A3A9-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ZNF714 | SNV | Missense_Mutation | rs760638774 | c.1202A>T | p.Glu401Val | p.E401V | protein_coding | deleterious(0.01) | possibly_damaging(0.877) | TCGA-DD-AADS-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZNF714 | SNV | Missense_Mutation | novel | c.1513N>T | p.Gly505Cys | p.G505C | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF714 | SNV | Missense_Mutation | novel | c.1416N>G | p.Asn472Lys | p.N472K | protein_coding | tolerated(1) | benign(0) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ZNF714 | SNV | Missense_Mutation | novel | c.716N>G | p.Tyr239Cys | p.Y239C | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD | |
ZNF714 | SNV | Missense_Mutation | novel | c.1285N>C | p.Glu429Gln | p.E429Q | protein_coding | deleterious(0.02) | benign(0.432) | TCGA-97-7546-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Targeted Molecular therapy | tarceva | SD | |
ZNF714 | SNV | Missense_Mutation | novel | c.241N>A | p.Glu81Lys | p.E81K | protein_coding | tolerated(0.24) | benign(0.303) | TCGA-MP-A4T8-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | navelbine | SD | |
ZNF714 | SNV | Missense_Mutation | novel | c.1508N>G | p.Gln503Arg | p.Q503R | protein_coding | deleterious(0.01) | benign(0.035) | TCGA-43-6770-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Vaccine | recprame+as15 | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |